Stem Cell Therapy - BioLogic Anti-Aging Skin Cream
http://www.ReadTheReviewsFirst.com Truvisage Anti-Aging Skin Care International Is Better Than Botox!

By: Greg Smith

Continued here:
Stem Cell Therapy - BioLogic Anti-Aging Skin Cream - Video

Stem Cell Therapy to Treat Equine Tendon Injuries
A brief explanation of tendon injuries and how stem cell therapy can be used to treat them.

By: Animal Science

View post:
Stem Cell Therapy to Treat Equine Tendon Injuries - Video

This active ingredient won the prize in European Innovation Best Active Ingredient in 2008. It is a revolutionary technology designed to protect human skin stem cells with the help of stem cells from a rare Swiss apple. The clinical trials conducted by the company who discovered this ingredient showed that 100% of the participants saw a reduction in fine lines and wrinkles after using a solution containing 2% PhytoCellTech Malus Domestica.

According to the Bible, Adam bit into an apple (coaxed on by us femme fatales) and deprived Earth of Heaven...was he attracted by the delicious taste or did he already know of the amazing youth-boosting properties of this fruit?

PhytoCellTec Malus Domestica is an award-winning patented liposomal preparation, so containing tiny bubbles made out of the same material as cell membranes, based on the stem cells of a rare Swiss apple called Uttwiler Sptlauber that derives from a seedling planted in the middle of the18th century. Uttwiler Sptlauber is an endangered apple variety that is well-known for its ability to be stored for long periods without shrivelling and thus its longevity potential. The apples are rich in phytonutrients, proteins and long-living cells. A novel technology has now been developed enabling the cultivation of rare and endangered species like Uttwiler Sptlauber. Thanks to this technology, plant stem cells can be obtained and incorporated into skin care products to enhance the longevity of skin cells. Not only does it protect the skins own stem cells but has been shown to have excellent age-delaying and anti-wrinkle properties, and is currently one of the most pioneering and exciting ingredients in skin care.

Stem Cells and Longevity

Longevity is related to specific cells called stem cells which have a unique growth characteristic. These cells can make identical copies of themselves as well as differentiate (in other words, split) to become separate, specialised cells. Two basic types of stem cells are present in the human body:

Embryonic stem cells found in blastocysts (structures found in the human pre-embryonic stage) can grow and differentiate into one of the more than 220 different cell types which make up the human body;

Adult stem cells located in some adult tissues can only differentiate into their own or related cell types. These cells act as a repair system for the body but also maintain the normal turnover of regenerative organs such as blood, skin or intestinal tissues.

Research on Stem Cells and Applications

Currently in medicine, adult stem cells are already used particularly in transplant medicine to treat leukemia and severe burns. In the cosmetic field, scientists are focusing their research on adult stem cells located in the skin. They are studying the potential of this type of cells, their functioning and aging. This research is helping us understand how to protect skin stem cells.

Stem Cells in the Human Skin

See the original post here:
Swiss Apple Stem Cells for perfect skin. What do plant ...

New research has found evidence that stem cells could be used to correct genetic defects in skin and to treat certain rare diseases.

Three separate studies by scientists in the US, Europe and Japan have raised hopes that the methods could be used to develop treatments for a range of problems, including epidermolysis bullosa.

It is a disorder wheresufferers are born with extensive blistering and patches of missing skin.

They areleft with extremely fragile skin for all of their lives.

In the first study, the researchers used Induced Pluripotent Stem Cells (iPSCs) - adult cells that are reprogrammed to an embryonic stem cell-like state.

The scientists took diseased cells from three adult patients withepidermolysis bullosa.

The researchers converted the cells into iPSCs and used specialist tools to edit and fix the mutation in the genetic code responsible for defective collagen protein production, which causes the condition.

They then grew pieces of human skin that produced the correct collagen, and grafted them into mice where they lasted for three weeks.

It i's hoped the risk of rejection in humans will be minimal because the skin is made from the patient's own cells.

A second study confirmed these findings in the lab, showing that it is possible to genetically correct iPSCs from mice with epidermolysis bullosa and use the repaired cells to heal blistered skin.

Continued here:
Scientists use stem cells to correct skin defects

Irvine, California (PRWEB) November 27, 2014

The Ageless Derma skin care company has just released their latest development in the form of a facial mask that exfoliates skin with ingredients such as apple stem cells to renew the complexion and correct texture and tone. The companys Swiss Apple Stem Cell Mask incorporates the cells of a long-living rare apple with other revitalizing ingredients from nature to result in a gentle mask that is effective and calming.

The Swiss apple, Malus Domestica, has its beginnings that go as far back as 18th century Switzerland. Ageless Derma recognized the importance of this plants stem cell extract for its ability to keep the fruit fresh for extended periods of time without wrinkling or shriveling. The Swiss Apple Stem Cell Mask contains the scientific advances that come from the cultivation of these stem cells, having incorporated it into a powerful and effective facial mask to rejuvenate skin and keep wrinkles at bay.

The Swiss Apple Stem Cell Mask contains other natural ingredients that work together to keep skin at its purest and return youthful life to the complexion. Kaolin Clay from the earth absorbs toxins that can enter the skins surface due to environmental pollutants in the air. The clay helps draw out grime and purify skin. Sweet Almond Oil nourishes skin, and adds much needed moisture and smoothness. Safflower Oil improves the texture of skin; especially skin that has become roughened with time and sun exposure. The Safflower Oil in Swiss Apple Stem Cell Mask also locks in moisture and tones skin for a flawless and radiant complexion.

Ageless Derma added fruit extracts to the Swiss Apple Stem Cell Mask for added health and radiance. Pumpkin Fruit Ferment, Pineapple Enzyme, and Papaya Enzyme make this mask luscious and plush. Age-defying antioxidants are also included, with Green Tea Extract and Aloe Leaf Extract added for soothing and fighting free radicals.

The developers at Ageless Derma Skin Care know they are making something extraordinary happen. Their line of physician-grade skin care items incorporates an important philosophy: promoting overall skin health by delivering the most cutting-edge biotechnology and pure, natural ingredients to all of the skin's layers. This attitude continues to resonate to this day with the companys founder, Dr. Farid Mostamand, who nearly a decade ago began his journey to deliver the best skin care alternatives for people who want to have healthy and beautiful looking skin at any age. About this latest Ageless Derma product, Dr. Mostamand says, This natural enzymatic Swiss Apple Stem Cell Mask gently exfoliates dead skin cells that are blocking new cell turnover for a renewed and radiant complexion. This is accomplished without the use of unnatural chemicals that can harm your skins delicate balance.

Ageless Derma products are formulated in FDA-approved Labs. All ingredients are inspired by nature and enhanced by science. Ageless Derma products do not contain parabens or any other harsh additives, and they are never tested on animals. The company has developed five unique lines of products to address any skin type or condition.

Read the original post:
Ageless Derma Introduces Their Latest Innovation: Swiss Apple Stem Cell Mask

27.11.2014 - (idw) IMBA - Institut fr Molekulare Biotechnologie der sterreichischen Akademie der Wissenschaften GmbH

Scientists at IMBA Institute of Molecular Biotechnology of the Austrian Academy of Sciences in Vienna have made a major advancement towards a future therapy for butterfly children. A treatment with fibroblasts generated from induced pluripotent stem cells has been highly successful in mice. The next step is to establish this method in humans. Butterfly children suffer from Epidermolysis Bullosa (EB), a debilitating skin disease. It is caused by a genetic defect that leads to a deficiency or complete lack of various structural proteins. In one particularly severe form, the protein collagen 7 is either missing or present only in insufficient amounts. If that bond is missing, the skin forms blisters or tears at the slightest mechanical pressure, leading to wounds and inflammation that require extensive treatment with creams and bandages. Often these constant lesions also lead to aggressive forms of skin cancer.

Presently there is no cure for this disease. But there are promising approaches that could lead to successful treatments in the future. One of them is a method called fibroblast injection. In this procedure, fibroblasts are injected between the layers of the skin, where they can produce the necessary collagen 7.

Researchers at IMBA under the leadership of Arabella Meixner have now been successful in developing this method to treat mice affected by EB. The individual steps of this treatment have been worked out and carefully tested in many years of laboratory work, and the results have now been published in the scientific journal Science Translational Medicine.

First the scientists returned skin cells of the diseased mice to the stem cell stage and then repaired the genetic defect, the root cause of the disease. Then the researchers transformed stem cells back into fibroblasts.

Before the repaired fibroblasts could be reintroduced into the organism, measures to prevent inflammation or rejection were necessary. In this study the researchers conducted a type of toxicity test, and the results were very promising. After several months of observation, no adverse immune reactions occurred, and the risk of skin cancer did not increase. That is an important consideration because butterfly children already have a greatly increased risk of skin cancer.

The next step is to establish this skin stem cell treatment in humans. To achieve that, the IMBA scientists intend to look for partners with clinical experience. For severe forms of Epidermolysis Bullosa, a systemic application needs to be developed to spread the cells throughout the entire body via the bloodstream to reach epithelial tissues that are more difficult to access, for example the mucous membranes in the mouth or bowels. Often in butterfly children with milder forms of the disease, only certain areas of the skin are affected. The skin stem cell therapy with local injections successfully tested on mice could lead to a valuable treatment method in the very near future.

The project conducted by IMBA scientists was initiated by the patient organization DEBRA Austria, and has had the financial support of the association and of other generous supporters since 2009. DEBRA's mission is to ensure that butterfly children receive competent specialized medical care and to promote research into options to relieve and cure EB. Further thanks also go to our funding and cooperation partners sterreichische Lotterien and FK Austria Wien.

Original publication: Wenzel et. al., iPSC-based cell therapy for Recessive Dystrophic Epidermolysis Bullosa. Science Translational Medicine. 2014.

Scientific Contact: Dr. Arabella Meixner, Research Lead Tel. +43 664 2018084 arabella.meixner@imba.oeaw.ac.at Weitere Informationen:http://www.imba.oeaw.ac.at

Continued here:
Tremendous progress in the development of skin stem cell treatments for butterfly children

PUBLIC RELEASE DATE:

26-Nov-2014

Contact: Krista Conger kristac@stanford.edu 650-725-5371 Stanford University Medical Center @sumedicine

Induced pluripotent stem cells made from patients with a form of blistering skin disease can be genetically corrected and used to grow back healthy skin cells in laboratory dishes, researchers at the Stanford University School of Medicine have found. They've termed the new technique "therapeutic reprogramming."

The skin cells formed normal human skin when grafted onto the backs of laboratory mice, they said.

The findings represent a major advance in the battle against the disease, epidermolysis bullosa, in which the top layer of skin, called the epidermis, sloughs off with the slightest friction, leaving open wounds that are difficult to heal. Severely stricken children who survive into their late teens or early 20s often die from invasive squamous cell carcinoma, a skin cancer that can arise during repeated cycles of skin wounding and healing.

"Epidermolysis bullosa is a truly horrible, debilitating skin disease in which the top layer of skin is not properly anchored to the underlying layers," said Anthony Oro, MD, PhD, professor of dermatology. "When they are born, the trauma of birth rips away their skin, and they continue to suffer severe skin wounds that require constant bandaging and medical attention throughout their lives."

Stanford has one of the largest epidermolysis bullosa clinics in the world, with an extremely active and engaged population of patients and their families eager to help researchers. The Stanford Department of Dermatology has been working to find new treatments for the disease for over 20 years. The latest advance, in which researchers replaced the mutated, disease-causing gene in the donor-made induced pluripotent stem cells with a healthy version, was funded by an $11.7 million grant from the California Institute for Regenerative Medicine.

New avenue of treatment

"This treatment approach represents an entirely new paradigm for this disease," Oro said. "Normally, treatment has been confined to surgical approaches to repair damaged skin, or medical approaches to prevent and repair damage. But by replacing the faulty gene with a correct version in stem cells, and then converting those corrected stem cells to keratinocytes, we have the possibility of achieving a permanent fix -- replacing damaged areas with healthy, perfectly matched skin grafts."

Excerpt from:
Blistering skin disease may be treatable with 'therapeutic reprogramming,' researchers say

CINCINNATI -- The daughter of a Cincinnati Bengal who has already been through a lot spent another day in the hospital for treatment Tuesday.

Leah Still -- Devon Stills daughter -- underwent a stem cell transplant procedure at Children's Hospital of Philadelphia. The stem cell treatment is an effort to regenerate her bone marrow and stem cells.

Stem cells definitely smell like corn...yall wasn't lying

Still flew to Philadelphia Monday to be with Leah. They went shopping at a mall.

The smile you have after shutting down the mall, literally. This girl had security and the... http://t.co/HHWtLhf4pf pic.twitter.com/QFRMJsdlCX

Still tweeted another photo Tuesday while they waited for her treatment to begin.

Selfies in the hospital to pass time by as we wait for the stem cells http://t.co/q6JZOIyi9q pic.twitter.com/ogB0J0Gitg

Leah was diagnosed with stage 4 neuroblastoma in June. She had surgery to remove a tumor from her abdomen in September, followed by chemotherapy to try to remove the cancer from her bone marrow.

She has already been treated with a round of chemotherapy and radiation.

Still said the family hopes that will be her only round of chemo and radiation but that it depends on how her results come back. He said it will take four to six weeks to determine if more treatments are necessary.

Follow this link:
Leah Still to undergo stem cell therapy

Calorie counts mandated at chain restaurants Calorie counts mandated at chain restaurants

New rules announced Tuesday by the U.S. Food and Drug Administration will have many restaurant chains posting calorie counts on their menus, and the rules even apply to movie theater popcorn and ice cream parlor fare.

New rules announced Tuesday by the U.S. Food and Drug Administration will have many restaurant chains posting calorie counts on their menus, and the rules even apply to movie theater popcorn and ice cream parlor fare.

Eating a serving a day of yogurt may lower your risk of developing Type 2 diabetes, new research suggests.

Eating a serving a day of yogurt may lower your risk of developing Type 2 diabetes, new research suggests.

Dutch researchers have developed a device that may reduce the discomfort many women feel during a mammogram while preserving the quality of the image.

Dutch researchers have developed a device that may reduce the discomfort many women feel during a mammogram while preserving the quality of the image.

A brain abnormality may be responsible for more than 40 percent of deaths from sudden infant death syndrome (SIDS), a new study suggests.

A brain abnormality may be responsible for more than 40 percent of deaths from sudden infant death syndrome (SIDS), a new study suggests.

Driving a large vehicle and being a young male are among the factors that improve a person's chances of surviving a car crash, a new study finds.

Continued here:
Researchers find stem cells that help nails regenerate

A team led by scientists from The Scripps Research Institute (TSRI) has found a simple method to convert human skin cells into the specialized neurons that detect pain, itch, touch and other bodily sensations. These neurons are also affected by spinal cord injury and involved in Friedreich's ataxia, a devastating and currently incurable neurodegenerative disease that largely strikes children.

The discovery allows this broad class of human neurons and their sensory mechanisms to be studied relatively easily in the laboratory. The "induced sensory neurons" generated by this method should also be useful in the testing of potential new therapies for pain, itch and related conditions.

"Following on the work of TSRI Professor Ardem Patapoutian, who has identified many of the genes that endow these neurons with selective responses to temperature, pain and pressure, we have found a way to produce induced sensory neurons from humans where these genes can be expressed in their 'normal' cellular environment," said Associate Professor Kristin K. Baldwin, an investigator in TSRI's Dorris Neuroscience Center. "This method is rapid, robust and scalable. Therefore we hope that these induced sensory neurons will allow our group and others to identify new compounds that block pain and itch and to better understand and treat neurodegenerative disease and spinal cord injury."

The report by Baldwin's team appears as an advance online publication in Nature Neuroscience on November 24, 2014.

In Search of a Better Model

The neurons that can be made with the new technique normally reside in clusters called dorsal root ganglia (DRG) along the outer spine. DRG sensory neurons extend their nerve fibers into the skin, muscle and joints all over the body, where they variously detect gentle touch, painful touch, heat, cold, wounds and inflammation, itch-inducing substances, chemical irritants, vibrations, the fullness of the bladder and colon, and even information about how the body and its limbs are positioned. Recently these neurons have also been linked to aging and to autoimmune disease.

Because of the difficulties involved in harvesting and culturing adult human neurons, most research on DRG neurons has been done in mice. But mice are of limited use in understanding the human version of this broad "somatosensory" system.

"Mouse models don't represent the full diversity of the human response," said Joel W. Blanchard, a PhD candidate in the Baldwin laboratory who was co-lead author of the study with Research Associate Kevin T. Eade.

A New Identity

For the new study, the team used a cell-reprogramming technique (similar to those used to reprogram skin cells into stem cells) to generate human DRG-type sensory neurons from ordinary skin cells called fibroblasts.

Read this article:
Pain and itch in a dish: Scientists convert human skin cells into sensory neurons

November 25, 2014

Chuck Bednar for redOrbit.com Your Universe Online

Two different teams of researchers, one led by scientists from The Scripps Research Institute (TSRI) and the other involving members of the Harvard Stem Cell Institute (HSCI) have discovered ways to create the neurons that detect pain, itch and other sensations in laboratory conditions out of human and mouse skin cells.

The TSRI study, which was published online Monday in the journal Nature Neuroscience, used what the authors referred to as a simple technique to create neurons that normally reside in clusters called dorsal root ganglia (DRG) along the outer spine. Those neurons are often affected by spinal cord injuries and a neurodegenerative condition known as Friedreichs ataxia.

According to the researchers, DRG sensory neurons extend their nerve fibers into skin, muscle and joints located throughout the body. The neurons are capable of alternately detecting gentle touch, painful contact, heat, cold, wounds, inflammation, chemical irritants, itch-inducing agents and fullness of the bowels and bladder. They also relay information about the position of the body and limbs, and have been linked to aging and autoimmune disease.

Due to the difficulties involved in culturing adult human neurons, most research relating to DRG neurons has been done in mice. However, the rodents are of limited use in understanding the human version of this somatosensory system, TSRI explained. The new discovery will allow this type of human neurons and their associated sensory mechanisms to be studied with relative ease in laboratory conditions, according to the study authors.

We have found a way to produce induced sensory neurons from humans where these genes can be expressed in their normal cellular environment, associate professor Kristin K. Baldwin, an investigator in TSRIs Dorris Neuroscience Center, said in a statement. This method is rapid, robust and scalable. Therefore we hope that these induced sensory neurons will allow our group and others to identify new compounds that block pain and itch and to better understand and treat neurodegenerative disease and spinal cord injury.

Similarly, the HSCI-led study, which included experts from Boston Childrens Hospital (BCH) and Harvards Department of Stem Cell and Regenerative Biology (HSCRB), was able to successfully convert mouse and human skin cells into pain-sensing neurons that responded to several different types of stimuli responsible for causing both acute and inflammatory pain.

The authors of this study, which also appeared in Wednesdays online edition of Nature Neuroscience, said that their research could help scientists better understand the different types of pain that we experience, as well as better identify why people respond to pain in different ways and why some individuals are more or less likely to develop chronic pain. It could also result in the development of improved pain-relieving medications.

The six-year project resulted in the creation of neuronal pain receptors that respond to both the types of intense stimuli triggered by a physical injury, and the more subtle stimuli triggered by inflammation which results in pain tenderness. The researchers report that the fact the neurons can respond to both the gross and fine forms of stimulation which produce separate types of pain in humans confirm that they are functionally normal.

More here:
Pain-Sensing Neurons Created From Human, Mouse Skin Cells

November 25, 2014

Provided by Peter Bracke, UCLA

Understanding the self-replication mechanisms is critical for improving stem cell therapies for blood-related diseases and cancers

Led by Dr. Hanna Mikkola, a member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, UCLA scientists have discovered a protein that is integral to the self-replication of hematopoietic stem cells during human development.

The discovery lays the groundwork for researchers to generate hematopoietic stem cells in the lab that better mirror those that develop in their natural environment. This could in turn lead to improved therapies for blood-related diseases and cancers by enabling the creation of patient-specific blood stem cells for transplantation.

The findings are reported online ahead of print in the journal Cell Stem Cell.

Researchers have long been stymied in their efforts to make cell-based therapies for blood and immune diseases more broadly available, because of an inability to generate and expand human hematopoietic stem cells (HSCs) in lab cultures. They have sought to harness the promise of pluripotent stem cells (PSCs), which can transform into almost any cell in the human body, to overcome this roadblock. HSCs are the blood-forming cells that serve as the critical link between PSCs and fully differentiated cells of the blood system. The ability of HSCs to self-renew (replicate themselves) and differentiate to all blood cell types, is determined in part by the environment that the stem cell came from, called the niche.

In the five-year study, Mikkola, Dr. Sacha Prashad and Dr. Vincenzo Calvanese, members of Mikkolas lab and lead authors of the study, investigated a HSC surface protein called GPI-80. They found that it was produced by a specific subpopulation of human fetal hematopoietic cells that were the only group that could self-renew and differentiate into various blood cell types. They also found that this subpopulation of hematopoietic cells was the sole population able to permanently integrate into and thrive within the blood system of a recipient mouse.

Mikkola and colleagues further discovered that GPI-80 identifies HSCs during multiple phases of human HSC development and migration. These include the early first trimester of fetal development when newly generated human hematopoietic stem cells can be found in the placenta, and the second trimester when HSCs are actively replicating in the fetal liver and the fetal bone marrow.

We found that whatever HSC niche we investigated, we could use GPI-80 as the best determinant to find the stem cell as it was being generated or colonized different hematopoietic tissues, said Mikkola, associate professor of molecular, cell and development biology at UCLA and also a member of the Jonsson Comprehensive Cancer Center. Moreover, loss of GPI-80 caused the stem cells to differentiate into mature blood cells rather than HSCs. This essentially tells us that GPI-80 must be present to make HSCs. We now have a very unique marker for investigating how human hematopoietic cells develop, migrate and function.

Original post:
UCLA Researchers Identify Protein Key To The Development Of Blood Stem Cells

Stem Cell Therapy at EmCell clinic: Dr. Khalil Fadel story

By:

See more here:
Stem Cell Therapy at EmCell clinic: Dr. Khalil Fadel story - Video

Freeport, Grand Bahama (PRWEB) November 25, 2014

Okyanos, the leader in cell therapy, announced the adoption of body-jet eco for use in the harvesting of adult stem cells for use in cell therapy. The Okyanos procedure begins with the extraction of a small amount of body fat, a process done using advanced water-jet assisted liposuction technology. The body-jet eco system is utilized during this procedure and allows a larger number of viable adult stem cells to be harvested. After separating the cells from fat tissue, the Okyanos medical doctor immediately injects these cells into and around the area needing treatment allowing targeting of the cells to repair damaged tissue.

According to Dr. Todd Malan, Chief Cell Therapy Officer and General Surgeon at Okyanos, who was involved in helping develop the appropriate settings of the body-jet eco use in adult stem cell harvesting, The body-jet eco was used during our first stem cell procedure at Okyanos. It performed flawlessly as expected and we feel it meets our tough standards. This is much gentler and more precise, making the overall procedure faster with less trauma to the surrounding tissue and less diversion of the adult stem cells from the intended area.

The body-jet eco is part of the water-jet assisted liposuction (WAL) family of devices, which detaches the fat gently from the tissue structure using a flat, fan-shaped water jet spray. The surrounding connective tissue, nerves and blood vessels remain in-tact which makes this procedure much gentler on the patient and leads to a quicker recovery with less pain medication required. The WAL process has a very high viability of fat cells and stem cells with a high take rate after fat grafting. The WAL family of devices is manufactured by human med AG with its headquarters in Schwerin, Germany, and distributed in North America by CAREstream America with its headquarters in Altamonte Springs, Florida.

Because the treatment is minimally invasive it requires that patients be under only moderate sedation. Post-procedural recovery consists of rest in a private suite for several hours that comfortably accommodates up to 3 family members.

Patients can contact Okyanos at http://www.okyanos.com or by calling toll free at 1-855-659-2667.

About CAREstream America: CAREstream America began in 2013 and is a division of CAREstream Medical Ltd, which has serviced Canadian customers respiratory and anesthesia needs for over 15 years. CAREstream America retains North American distribution rights to the full water-jet assisted human med AG product line. CAREstream America is the premier distributor of Aesthetic product lines ranging from water-jet assisted technology to vascular access imaging to nitrous oxide analgesia which help shape the body, showcase the veins and relieve the pain and anxiety of aesthetic procedures.

About Dr. Malan: Todd Malan, MD, serves as the Chief Cell Therapy Officer and General Surgeon at Okyanos Heart Institute, overseeing the liposuction and stem cell isolation step of the Okyanos cardiac cell therapy process. Known as an innovative cosmetic surgeon, Dr. Malans practices combine the most progressive and minimally-traumatic liposuction technologies available. A pioneer of fat-derived stem cell therapies, he became the first physician in the US to utilize stem cells from fat for soft tissue reconstruction in October, 2009, combining water-assisted liposuction, fat transfer and adult stem cell technologies.

About Okyanos: (Oh key AH nos) Based in Freeport, Grand Bahama, Okyanos brings a new standard of care and a better quality of life to patients with coronary artery disease, tissue ischemia, autoimmune diseases, and other chronic neurological and orthopedic conditions. Okyanos Cell Therapy utilizes a unique blend of stem and regenerative cells derived from patients own adipose (fat) tissue which helps improve blood flow, moderate destructive immune response and prevent further cell death. Okyanos is fully licensed under the Bahamas Stem Cell Therapy and Research Act and adheres to U.S. surgical center standards. The literary name Okyanos, the Greek god of the river Okyanos, symbolizes restoration of blood flow.

Visit link:
Okyanos Adopts WAL/ body-jet eco for Use in Cell Therapy

Contact Information

Available for logged-in reporters only

Newswise In a study led by Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research member, Dr. John Chute, UCLA scientists have for the first time identified a unique protein that plays a key role in regulating blood stem cell replication in humans.

This discovery lays the groundwork for a better understanding of how this protein controls blood stem cell growth and regeneration, and could lead to the development of more effective therapies for a wide range of blood diseases and cancers.

The study was published online November 21, 2014 ahead of print in the Journal of Clinical Investigation.

Hematopoietic stem cells (HSCs) are the blood-forming cells that have the remarkable capacity to both self-renew and give rise to all of the differentiated cells (fully developed cells) of the blood system. HSC transplantation provides curative therapy for thousands of patients annually. However, little is known about the process through which transplanted HSCs replicate following their arrival in human bone marrow. In this study, the authors showed that a cell surface protein called protein tyrosine phosphatase-sigma (PTP-sigma) regulates the critical process called engraftment, meaning how HSCs start to grow and make health blood cells after transplantation.

Mamle Quarmyne, a graduate student the lab of Dr. Chute and first author of the study, demonstrated that PTP-sigma is produced (expressed) on a high percentage of mouse and human HSCs. She showed further that genetic deletion of PTP-sigma in mice markedly increased the ability of HSCs to engraft in transplanted mice.

In a complementary study, she demonstrated that selection of human blood HSCs which did not express PTP-sigma led to a 15-fold increase in HSC engraftment in transplanted immune-deficient mice. Taken together, these studies showed that PTP-sigma suppresses normal HSC engraftment capacity and targeted blockade of PTP-sigma can substantially improve mouse and human HSC engraftment after transplantation.

Chute and colleagues showed further that PTP-sigma regulates HSC function by suppressing a protein, RAC1, which is known to promote HSC engraftment after transplantation.

These findings have tremendous therapeutic potential since we have identified a new receptor on HSCs, PTP-sigma, which can be specifically targeted as a means to potently increase the engraftment of transplanted HSCs in patients, said Chute, senior author of the study and UCLA Professor of Hematology/Oncology and Radiation Oncology. This approach can also potentially accelerate hematologic recovery in cancer patients receiving chemotherapy and/or radiation, which also suppress the blood and immune systems.

Read more:
UCLA Researchers Unlock Protein Key to Harnessing Regenerative Power of Blood Stem Cells

Previous studieshaveunsuccessfullytried to producenerve cells from embryonic stem cells For the recent study, a team of USresearchers used adult tissue instead They were able to reprogram ordinary skin cells into induced stem cells Scientistsat Harvard Medical School in Massachusetts used a cocktail of proteins called transcription factors that control the activity of genes Study could help reveal the origins of pain and develop better drugs

By Sarah Griffiths for MailOnline

Published: 13:04 EST, 24 November 2014 | Updated: 13:16 EST, 24 November 2014

Pain is a complex and unpleasant sensation, which some people feel more acutely than others - and its origins remain largely a mystery.

Now, scientists have created pain in a dish by converting skin cells into sensitive neurons in a bid to learn more about these sensations.

The lab-created nerve cells respond to a range of different kinds of pain stimulation, including physical injury, chronic inflammation and cancer chemotherapy.

Scientists have created pain in a dish by converting skin cells into sensitive neurons (illustrated) in a bid to learn more about its origins.In the future, the research could be used to develop better pain-relieving drugs

And in the future, the custom-made neurons could be used to investigate the origins of pain and develop better pain-relieving drugs.

The work follows years of unsuccessful attempts to produce nerve cells from embryonic stem cells, which are immature blank slate cells with the potential to become any tissue in the body.

A nociceptor is a receptor of a nerve cell that responds to potentially damaging stimuli by sending signals to the spinal cord and brain.

See the rest here:
Nerve cells 'grown' in a lab could reveal more about how injury affects the body

Researchers found stem cells in mouse nails that performed two roles They cause nails to grow, and focus on repair when it is lost or injured The experts tracked how stem cells in the nails of mice split and grow It is hoped the same cells could be manipulated to grow tissue in other body parts

By Ellie Zolfagharifard for MailOnline

Published: 10:23 EST, 24 November 2014 | Updated: 10:23 EST, 24 November 2014

The blue-tailed skink has the remarkable ability to lose its tail to distract predators, and then grow a new one.

And someday, thanks to cells found in our nails, humans could have similar lizard-like abilities that will help us regrow lost limbs.

Researchers in the US recently found unique stem cells in nails that perform two roles - they cause nails to grow, and they focus on nail repair when it is lost or injured.

Researchers in the US recently found unique stem cells (shown in the above animation) in nails that perform two roles; they cause nails to grow, and focus on nail repair when it is lost or injured

The researchers claim these stem cells could be manipulated to grow tissue for other body parts, helping to someday recover lost limbs or organs.

The elusive stem cells were found at the University of Southern California by attaching dyes as 'labels' on mouse nail cells.

Many of these cells repeatedly divided, diluting the dyes and labels in the process.

See the rest here:
Could nails help us regrow LIMBS? Stem cells found on fingers and toes could someday give humans lizard-like abilities

Scientists have created pain in a dish by converting skin cells into sensitive neurons.

The laboratory-generated nerve cells respond to a range of different kinds of pain stimulation, including physical injury, chronic inflammation, and cancer chemotherapy.

In future they could be used to investigate the origins of pain and develop better pain-relieving drugs.

The work followed years of unsuccessful attempts to produce nerve cells from embryonic stem cells, immature blank slate cells with the potential to become any tissue in the body.

A turning point came with the development of technology that allowed ordinary skin cells to be re-programmed into induced stem cells.

A team led by Dr Clifford Woolf at Harvard Medical School used a cocktail of transcription factors proteins that control the activity of genes to transform mouse and human skin cells directly into pain-sensing neurons.

The researchers, whose findings are reported in the journal Nature Neuroscience, were able to model pain hypersensitivity experienced by patients who donated skin cells to the study.

Originally posted here:
Scientists have created 'pain in a dish'

PUBLIC RELEASE DATE:

24-Nov-2014

Contact: Jen Middleton jen.middleton@ed.ac.uk 44-131-650-6514 University of Edinburgh @uniofedinburgh

Liver disease patients could be helped by a new cell therapy to treat the condition.

Researchers from the University of Edinburgh have received funding to start testing the therapy in patients within the next year.

It will be the world's first clinical trial of a new type of cell therapy to treat liver cirrhosis, a common disease where scar tissue forms in the organ as a result of long-term damage.

The Edinburgh team has received funding from the Medical Research Council and Innovate UK to investigate the disease, which claims 4000 lives in the UK each year.

The only successful treatment for end-stage liver cirrhosis at present is an organ transplant. The new therapy is based on a type of white blood cell called a macrophage, which is key to normal repair processes in the liver.

Macrophages reduce scar tissue and stimulate the liver's own stem cells to expand and form into healthy new liver cells.

Scientists will take cells from the blood of patients with liver cirrhosis and turn them into macrophages in the lab using chemical signals.

View post:
Cell therapy trial offers new hope to liver disease patients

Cambridge stem cell pioneer DefiniGEN is in China this week showcasing technology that arguably gives the UK a world lead in countering liver and pancreatic cancer.

The young company is seeking Chinese partners to broaden the reach of the technology which holds a potentially significant payback in regenerative medicine.

With US global stem cell innovator Roger Pedersen among its technology founders, DefiniGEN was founded two years ago to commercialise a stem cell production platform developed at the University of Cambridge.

The platform generates human liver and pancreatic cell types using Nobel Prize winning human Induced Pluripotent Stem Cell (iPSC) technology.

DefiniGEN is visiting Shanghai and Beijing on a trade mission organised by UKTI East of England in partnership with the China-Britain Business Council.

The company is actively looking to partner with Life Science distributors and pharmaceutical drug discovery companies in China. CEO Dr Marcus Yeo and Dr Masashi Matsunaga business development manager for Asia Pacific - are spearheading the initiative.

The visit includes a range of medically-focused ventures from one to one meetings with key players to presentations at UK consulates.

DefiniGEN cells are provided to the drug discovery sector for use in lead optimisation and toxicity programmes.

The companys OptiDIFF platform produces validated libraries of disease-modelled human liver cells for a range of diseases. The phenotype (the composite of an organisms traits) and pathology of the diseases is pre-confirmed in the cells.

The technology provides pharmaceutical companies with more predictive in vitro cell products enabling the development of safer and more effective treatments.

Original post:
Cambridge stem cell pioneer targets China partners